David Sallman, MD is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center and assistant professor in the Department of Oncologic Sciences at the University of South Florida, both in Tampa, Florida. He is also the myeloid section head of the Malignant Hematology Department. Dr Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies (phase 1 and 2 clinical trials) for patients with MDS and AML, based on the underlying mutational drivers of each disease. Specifically, he studies the genetic drivers of myeloid diseases to improve prognostication for patients and to allow for more personalized treatment and has published significantly on this topic.
Dr. Sallman is the principal investigator for multiple ongoing studies focused on higher-risk MDS, including his recent work on TP53-mutant MDS, and he has been the lead principal investigator for phase 1-3 trials TP53-mutant MDS and AML patients. Additionally, he serves as lead PI for multiple cellular therapy trials including CAR-T and TCR therapies. Dr. Sallman has authored or coauthored numerous articles, books, book chapters, and abstracts and serves as reviewer for multiple journals. He received the Young Investigator Grant from the MDS Foundation in 2017 and the Dresner Foundation Career Development award in 2018.
Dr. Sallman earned his medical degree from the University of South Florida College of Medicine and completed an internal medicine residency at Massachusetts General Hospital before completing a hematology/oncology fellowship at Moffitt Cancer Center. He is board certified in medical oncology, hematology, and internal medicine.